PMC/PubMed Indexed Articles
Indexed In
- Open J Gate
- Academic Keys
- RefSeek
- Hamdard University
- EBSCO A-Z
- Publons
- Geneva Foundation for Medical Education and Research
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
EFFECT OF LIRAGLUTIDE ON FAT DISTRIBUTION IN TYPE 1 DIABETES
7th World Congress on Healthcare & Technologies
September 26-27, 2016 London, UK
Marie-Christine Dube, Martin D Amours and S. John Weisnagel
CHU de Québec-Université Laval, Canada
Scientific Tracks Abstracts: Health Care: Current Reviews
Abstract:
We investigated the effect of 24 weeks of treatment with Liraglutide 1.8 mg combined with basal/bolus insulin regimen on fat distribution in overweight subjects with type 1 diabetes. In a double-blind, cross-over fashion, participants (n = 15) were assigned to insulin + placebo or insulin + Liraglutide for 24 weeks including a one-month titration period. Measures of fat distribution (waist and hip circumferences, skinfold thickness, percentage of body fatness, abdominal and midthigh computed tomography scans) were obtained in 15 overweight participants under the baseline, Liraglutide and placebo conditions. Paired t tests were used to compare the changes in metabolic and anthropometric parameters. With Liraglutide, all markers of fat distribution decreased clinically and significantly. BMI decreased since 30.5 ± 0.9 to 28.5 ± 1.0 kg/m2, waist and hip circumferences each decreased by about 3 cm. The sum of skinfold thickness decreased from 220 ± 45 to 176 ± 12 mm. Percentage of body fat went from 33.2 ± 1.6 to 31.3 ± 1.8% (all p < 0.05). Total and subcutaneous adipose tissue decreased significantly (p < 0.0005), decrease in visceral adipose tissue was of borderline significance (p = 0.057). With Liraglutide, changes in VAT from baseline were correlated with changes in insulin sensitivity. The addition of Liraglutide to basal/bolus insulin therapy for 24 weeks in overweight participants with type 1 diabetes significantly improved fat distribution and related metabolic parameters. Longer term studies evaluating clinical endpoints will be required to further document the role of GLP- 1 agonist therapy in type 1 diabetes.
Biography :
Marie-Christine Dubé completed her PhD in physiology and endocrinology from University Laval in 2006. Since then, she has been working in diabetes research at CHU de Québec-University Laval. She has published more than 20 papers in reputed journals.